URIST MARSHALL (EVP & Co-Head Research & Inv.) sold 12.5% of their position (20K shares) of ROYALTY PHARMA PLC on the open market
Open‑market sale worth $766.4K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 12/17/2025ACC: 0001838139-25-000010
Officer· EVP & Co-Head Research & Inv.
Since Dec 2020
-20K
Net shares
Net seller
$766.4K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
20K disposed
Non-Derivative Transactions1
Class A Ordinary Shares
Indirect
Shares
−20K
Price / share
$38.32
Trade value
$766.42K
% of position
12.5%
12/16/2025
160K→140K
Total
Net shares
−20K
Net value
-$766.42K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary Shares Indirect | 12/16/2025 | S · Sale | −20K | $38.32 | $766.42K | 12.5% | 160K | 140K |
| Total | −20K | -$766.42K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Class A Ordinary Shares
DirectShares owned7.40K
Class A Ordinary Shares
IndirectShares owned19.02K
Total
7.40K direct·19.02K indirect26.42K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Ordinary Shares | 7.40K | Direct |
| Class A Ordinary Shares | 19.02K | Indirect |
| Total | 26.42K | 7.40K direct·19.02K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported